Seeking Alpha

J&J to appeal Chinese ruling over diabetes trademark

  • Johnson & Johnson (JNJ) plans to appeal a ruling by China's State Administration for Industry & Commerce (SAIC) to cancel the company's exclusive rights to the trademark for its OneTouch diabetes monitoring products.
  • If upheld, SAIC's decision could pave the way for competitors to sell rival and cheaper products under the same name.
  • China has around 100M diabetes sufferers, the largest number in the world.
  • Separately, J&J has asked the FDA to require that biosimilars, which are copies of biological treatments, bear a similar but not identical name to reference therapies.
  • In contrast, Novartis and Mylan want biosimilars to use the same international non-proprietary name.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|